Table 1.
Compound # |
Formal Name |
Compound Structure | Derivative series (a) |
Inhibition of HBV RNaseH |
HBV replication inhibition (EC50,μ3M) (e) |
HSV-1 suppression (log10 at 5 μM) (f) |
Inhibition of huRNaseH1 (b) |
Toxicity in HepDES19 (g) | TI | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Oligo- nucleotide directed cleavage assay (b, c) |
Molecular Beacon cleavage assay (d) |
MTS | NR | LDH | ||||||||
208 | Sun B8155 | HPD | + | + | 0.69 ± 0.2 | − | − | 15 ± 7 | 13 ± 1 | 12 ± 0.1 | 22 | |
211 | Rilopirox | HPD | − | − | − | − | − | |||||
86 | VS42 | HID | − | − | 1.4 ± 0.3 | − | + | 99 ± 2 | 52 ± 11 | >100 | 71 | |
83 | MB88 | HID | − | + | 2.3 ± 1.6 | − | + | 100± 35 | >100 | >100 | 43 | |
88 | VS45 | HID | − | − | 2.5 ± 0.5 | − | + | 40 ± 6 | 26 ± 2 | 57 ± 6 | 16 | |
89 | VS51 | HID | − | − | 2.6 ± 0.8 | − | + | 28 ± 8 | 19 ± 3 | 25 ± 4 | 11 | |
1 | TRC 939800 | HID | + | + | 4.2 ± 1.4 (b) | − | + | 75 ± 24 | 81 ± 4 | 79 ± 12 | 18 | |
81 | MB4 | HID | − | + | 4.4 ± 3.0 | − | + | 57 ± 16 | 31 ± 7 | 24 ± 5 | 13 | |
91 | MB106 | HID | − | − | 4.6 ± 1.0 | − | + | 11 ± 4 | 33 ± 3 | 58 ± 22 | 2.4 | |
87 | VS55 | HID | − | − | 4.5 ± 3.7 | − | + | 37 ± 17 | 24 ± 1 | 52 ± 15 | 8.2 | |
85 | MB103 | HID | − | − | 6.5 ± 1.5 | − | + | 29 ± 12 | 67 ± 13 | >100 | 4.5 | |
84 | MB105 | HID | − | − | 6.5 ± 4.5 | − | + | 23 ± 9 | 32 ± 8 | 37 ± 15 | 3.5 | |
90 | MB104 | HID | − | − | 19 ± 0.9 | − | + | 88 ± 17 | >100 | >100 | 4.6 | |
82 | MB71 | HID | − | − | − | + | ||||||
78 | MB1 | HID | − | − | − | + | ||||||
79 | MB2 | HID | − | − | − | − | ||||||
80 | MB3 | HID | − | − | − | − | ||||||
41 | TRC C432800 (Ciclopirox) | POH | − | − | 5.0 | + | ||||||
42 | Labotest 72543251 | POH | − | − | − | + | ||||||
43 | Sigma PH008969 | POH | − | − | − | − | ||||||
44 | Labotest 12243782 | POH | − | − | − | − | ||||||
45 | TCI America H1040 | HID | − | − | − | − | ||||||
128 | Aldrichselect CNC_ID100615760 | POH | − | − | − | − | ||||||
132 | Aldrichselect CNC_ID 389306767 | POH | − | − | ||||||||
138 | Sigma H53704 | POH | − | − | − | − | − | |||||
139 | Sigma 130672 | POH | − | − | − | |||||||
140 | Chembridge 6325462 | POH | − | − | − | + | ||||||
191 | Piroctone olamine | POH | − | − | 4.6 | − | ||||||
197 | Benzoylene urea | POH | − | − | − | − | ||||||
198 | 2,3-dihydroxy-quinoxaline | POH | − | − | − | − | ||||||
204 | AK-830/13217043 | POH | − | − | − | + | ||||||
206 | AJ-333/25006202 | POH | − | − | − | + | ||||||
217 | Visas M Lab 444035142 | POH | − | − | − | + | ||||||
236 | ZF4 | FLT | − | − | − | − | ||||||
237 | ZF13 | FLT | − | − | − | |||||||
238 | ZF18 | FLT | − | − | − | |||||||
239 | ZF19 | FLT | − | − | − | |||||||
240 | ZF24 | FLT | − | − | − | + | ||||||
241 | ZF29 | FLT | − | − | − |
N-hydroxyisoquinolinedione (HID), polyoxygenated heterocycles (POH), N-hydroxypyridinediones (HPD), and flutimides (FLT)
Compounds 1–91, and 138–140 previously reported in (Cai et al., 2014)
(+), Dose-dependent inhibition at ≤100 μM; (−), No inhibition detected at 100 μM
(+), Dose-dependent inhibition at ≤500 μM; (−), No inhibition detected at 500 μM
(−), No inhibition detected at 20 μM
(−), ≤1 log10 suppression of plaque forming units at 5 μM
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (MTS), neutral red retention assay (NR), lactate dehydrogenase release (LDH)